Ottawa, ON GlaxoSmithKline has asked the Canadian government to hold back a batch of H1N1 vaccine that could be linked to a higher rate of severe allergic reactions. The batch that is being held back was shipped in late October and had the lot number A80CA007A. Approximately 170,000 doses are affected by the recall.
November 22, 2009. By Heidi Turner.
